Patents by Inventor Jeffrey C. Webster

Jeffrey C. Webster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Rage fusion proteins and methods of use
    Patent number: 8877192
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Grant
    Filed: January 3, 2011
    Date of Patent: November 4, 2014
    Assignee: TransTech Pharma, LLC
    Inventors: Adnan M. M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein
  • RAGE Fusion Protein Compositions And Methods Of Use
    Publication number: 20130142792
    Abstract: Disclosed are fusion proteins comprising a RAGE polypeptide, wherein the RAGE polypeptide comprises a fragment of a mammalian wild type RAGE peptide and at least one point mutation in the RAGE polypeptide portion of the fusion protein relative to the wild type RAGE peptide. The point mutation may remove and/or alter a glycosylation site or an enzyme cleavage site. Also disclosed are nucleic acids encoding such proteins as well as methods of using such proteins for treating RAGE-mediated pathologies.
    Type: Application
    Filed: October 19, 2010
    Publication date: June 6, 2013
    Inventors: Jeffrey C. Webster, Gregory T. Bleck, Madan Katragadda, Manoj Rajadhyaksha, Bernard N. Violand, Jo-Ann Wentland, Linda Marie Rothlein
  • Nucleic acid molecules encoding rage fusion proteins
    Patent number: 8344120
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin CH2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: January 1, 2013
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Robert Rothlein, Ye Edward Tian, Jeffrey C. Webster
  • Rage Fusion Proteins And Methods Of Use
    Publication number: 20120171202
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: January 3, 2011
    Publication date: July 5, 2012
    Inventors: ADNAN M.M. MJALLI, YE EDWARD TIAN, JEFFREY C. WEBSTER, ROBERT ROTHLEIN
  • Rage Fusion Proteins, Formulations And Methods Of Use Thereof
    Publication number: 20110282035
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin CH2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: June 13, 2011
    Publication date: November 17, 2011
    Inventors: Adnan M.M. Mjalli, Robert Rothlein, Ye Edward Tian, Jeffrey C. Webster, Eric J. Benjamin
  • Rage Fusion Proteins And Methods Of Use
    Publication number: 20110244516
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: February 17, 2011
    Publication date: October 6, 2011
    Inventors: Adnan M.M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein
  • Rage fusion proteins
    Patent number: 7981423
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Grant
    Filed: August 3, 2005
    Date of Patent: July 19, 2011
    Assignee: Transtech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Ye E. Tian, Jeffrey C. Webster, Robert Rothlein
  • RAGE fusion proteins, formulations, and methods of use thereof
    Patent number: 7981424
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin CH2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: July 19, 2011
    Assignee: Transtech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Robert Rothlein, Ye Edward Tian, Jeffrey C. Webster, Eric J. Benjamin
  • Rage Fusion Proteins And Methods Of Use
    Publication number: 20110124102
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: January 7, 2011
    Publication date: May 26, 2011
    Inventors: Adnan M.M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein
  • Immunoglobulin Fusion Proteins and Methods of Making
    Publication number: 20110110945
    Abstract: Disclosed are immunoglobulin fusion proteins and methods of making such proteins. In certain embodiments, the fusion protein may include a non-immunoglobulin polypeptide linked to an immunoglobulin polypeptide. In certain embodiments, the non-immunoglobulin polypeptide may comprise a region that replaces an immunoglobulin Fc hinge region, but that allows for correct assembly of the immunoglobulin chains.
    Type: Application
    Filed: October 6, 2010
    Publication date: May 12, 2011
    Applicant: TransTech Pharma, Inc.
    Inventors: Adnan M.M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein
  • Rage fusion proteins
    Patent number: 7901688
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Grant
    Filed: August 3, 2005
    Date of Patent: March 8, 2011
    Assignee: Transtech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein
  • Rage Fusion Proteins and Methods of Use
    Publication number: 20090060925
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: August 3, 2005
    Publication date: March 5, 2009
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF
    Inventors: Adnan M.M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein, David M. Stern, Ann Marie Schmidt, Shi Du Yan
  • Rage Fusion Proteins And Methods Of Use
    Publication number: 20090004190
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: January 23, 2007
    Publication date: January 1, 2009
    Inventors: Adnan M.M. Mjalli, Jeffrey C. Webster, Robert Rothlein, Ye E. Tian
  • Immunoglobulin fusion proteins and methods of making
    Publication number: 20080199467
    Abstract: Disclosed are immunoglobulin fusion proteins and methods of making such proteins. In certain embodiments, the fusion protein may include a non-immunoglobulin polypeptide linked to an immunoglobulin polypeptide. In certain embodiments, the non-immunoglobulin polypeptide may comprise a region that replaces an immunoglobulin Fc hinge region, but that allows for correct assembly of the immunoglobulin chains.
    Type: Application
    Filed: February 11, 2008
    Publication date: August 21, 2008
    Inventors: Adnan M. M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein